Model A   Model B   Model C   Model D  
  β p-value β p-value β p-value β p-value
Age -0.045 0.61 -0.028 0.74 -0.032 0.73 -0.050 0.58
Sex
(men/women)
-0.122 0.20 -0.152 0.095 -0.218 0.033 -0.029 0.79
Diabetes (yes/no) -0.016 0.87 -0.044 0.66 0.034 0.76 0.00 0.99
MetS (yes/no) 0.107 0.310 -0.052 0.63 0.126 0.260 0.142 0.19
VLDL particle concentration 0.280 0.003     0.257 0.014 0.324 0.001
LDL particle concentration 0.239 0.013 0.205 0.029     0.293 0.006
HDL particle concentration 0.013 0.88 0.000 1.00 -0.014 0.89    
Large VLDL     0.503 <0.001        
Medium VLDL     -0.051 0.67        
Small VLDL     -0.010 0.91        
IDL         0.125 0.169    
Large LDL         -0.040 0.68    
Small LDL         0.084 0.47    
Large HDL             0.096 0.45
Medium HDL             0.072 0.50
Small HDL             -0.080 0.48
VLDL: very low density lipoproteins; LDL: low density lipoproteins; HDL: high density lipoproteins. β: standardized regression coefficient.
Model A: model including age, sex, diabetes status, presence of MetS, VLDL, LDL and HDL particle concentrations
Model B: model including age, sex, diabetes status, presence of MetS, VLDL subfractions, LDL and HDL particle concentrations
Model C: model including age, sex, diabetes status, presence of MetS, LDL subfractions, and VLDL and HDL particle concentrations
Model D: model including age, sex, diabetes status, presence of MetS, HDL subfractions, and VLDL and LDL particle concentrations
Table 4: Multivariable linear regression analysis demonstrating relationships of plasma apolipoprotein E with lipoprotein subfractioncharacteristics in all subjects combined (60 subjects with metabolic syndrome (MetS) and 62 subjects without MetS)